Optimize Fall Flu Enrollment: HR+ Therapy, Spironolactone & HNSCC
Use fall's momentum to boost enrollment: prioritize HR+ targeted adoption, repurpose spironolactone for seniors, leverage flu-season touchpoints, and seize HNSCC market opportunities with cost-aware, inclusive strategies.
Robert Maxwell
Oct 22, 2025
HR+ breast cancer
glaucoma clinical research
HNSCC oncology trials
Spironolactone repurposing
